{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T23:17:11Z","timestamp":1783552631485,"version":"3.55.0"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":56,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Flemish Interuniversity Council \u2013 University Development Cooperation","award":["TZ2022TEA530A101"],"award-info":[{"award-number":["TZ2022TEA530A101"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"DOI":"10.1186\/s12889-026-27723-4","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T03:36:27Z","timestamp":1778729787000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Simulation modeling for the design and evaluation of HIV drug resistance interventions: a systematic review of literature"],"prefix":"10.1186","volume":"26","author":[{"given":"Beatrice Godwin","family":"Aiko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonor","family":"Guariguata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Myemba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Bwire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goodluck","family":"Nyondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael Z.","family":"Sangeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Japhet","family":"Killewo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nico","family":"Vandaele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Decouttere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"issue":"6","key":"27723_CR1","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1093\/CID\/CIAB583","volume":"74","author":"RP McClung","year":"2022","unstructured":"McClung RP, Oster AM, Ocfemia MCB, Saduvala N, Heneine W, Johnson JA, et al. Transmitted Drug Resistance Among Human Immunodeficiency Virus (HIV)-1 Diagnoses in the United States, 2014\u20132018. Clin Infect Dis. 2022;74(6):1055\u201362. https:\/\/doi.org\/10.1093\/CID\/CIAB583. PubMed PMID: 34175948.","journal-title":"Clin Infect Dis"},{"key":"27723_CR2","doi-asserted-by":"publisher","unstructured":"Lecher SL, Fonjungo P, Ellenberger D, Toure CA, Alemnji G, Bowen N, et al. HIV Viral Load Monitoring Among Patients Receiving Antiretroviral Therapy - Eight Sub-Saharan Africa Countries, 2013\u20132018. MMWR Morb Mortal Wkly Rep. 2021;70(21):775\u20138. https:\/\/doi.org\/10.15585\/MMWR.MM7021A2. PubMed PMID: 34043612.","DOI":"10.15585\/MMWR.MM7021A2"},{"key":"27723_CR3","unstructured":"Unaids. 2024 global AIDS report \u2014 The Urgency of Now: AIDS at a Crossroads. 2024. Available from: http:\/\/www.wipo.int\/."},{"issue":"9","key":"27723_CR4","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1093\/INFDIS\/JIX089","volume":"215","author":"AN Phillips","year":"2017","unstructured":"Phillips AN, Stover J, Cambiano V, Nakagawa F, Jordan MR, Pillay D, et al. Impact of HIV drug resistance on HIV\/AIDS-associated mortality, new infections, and antiretroviral therapy program costs in Sub-Saharan Africa. J Infect Dis. 2017;215(9):1362\u20135. https:\/\/doi.org\/10.1093\/INFDIS\/JIX089. PubMed PMID: 28329236.","journal-title":"J Infect Dis"},{"key":"27723_CR5","doi-asserted-by":"crossref","unstructured":"Cilento ME, Kirby KA, Sarafianos SG. Avoiding Drug Resistance in HIV Reverse Transcriptase. Chem Rev. 2021;121(6):3271\u201396. https:\/\/doi.org\/10.1021\/ACS.CHEMREV.0C00967\/ASSET\/IMAGES\/LARGE\/CR0C00967_0021.JPEG. PubMed PMID: 33507067.","DOI":"10.1021\/acs.chemrev.0c00967"},{"issue":"5","key":"27723_CR6","doi-asserted-by":"publisher","first-page":"e392","DOI":"10.1016\/S2666-5247(21)00250-0","volume":"3","author":"SY Rhee","year":"2022","unstructured":"Rhee SY, Kassaye SG, Jordan MR, Kouamou V, Katzenstein D, Shafer RW. Public availability of HIV-1 drug resistance sequence and treatment data: a systematic review. Lancet Microbe. 2022;3(5):e392\u20138. https:\/\/doi.org\/10.1016\/S2666-5247(21)00250-0.","journal-title":"Lancet Microbe"},{"key":"27723_CR7","unstructured":"World Health Organization. HIV Drug Resistance Report 2021. World Health Organization. 2021Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240038608. Cited 15 Dec 2024."},{"key":"27723_CR8","unstructured":"Global HIVH, and StiP (HHS). WHO Brief Report on HIV Drug Resistance 2024. World Health Organization (WHO). 2024. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240086319. Cited 15 Dec 2024."},{"key":"27723_CR9","unstructured":"World Health Organization. Global Action Plan on HIV drug resistance, 2017\u20132021. Geneva: World Health Organization. 2017;(July):36. Available from: https:\/\/apps.who.int\/iris\/handle\/10665\/255883. Cited 2 Oct 2025."},{"issue":"1","key":"27723_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12911-018-0707-6\/TABLES\/2","volume":"18","author":"L Freebairn","year":"2018","unstructured":"Freebairn L, Atkinson JA, Kelly PM, McDonnell G, Rychetnik L. Decision makers\u2019 experience of participatory dynamic simulation modelling: Methods for public health policy. BMC Med Inf Decis Mak. 2018;18(1):1\u201314. https:\/\/doi.org\/10.1186\/S12911-018-0707-6\/TABLES\/2. PubMed PMID: 30541523.","journal-title":"BMC Med Inf Decis Mak"},{"issue":"5","key":"27723_CR11","doi-asserted-by":"publisher","first-page":"e16103","DOI":"10.2196\/16103","volume":"9","author":"H Smith","year":"2020","unstructured":"Smith H, Varshoei P, Boushey R, Kuziemsky C. Use of Simulation Modeling to Inform Decision Making for Health Care Systems and Policy in Colorectal Cancer Screening: Protocol for a Systematic Review. JMIR Res Protoc. 2020;9(5):e16103. https:\/\/doi.org\/10.2196\/16103. PubMed PMID: 32401223.","journal-title":"JMIR Res Protoc"},{"key":"27723_CR12","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/J.JCLINEPI.2018.08.016","volume":"104","author":"TM Govers","year":"2018","unstructured":"Govers TM, Rovers MM, Brands MT, Dronkers EAC, Baatenburg de Jong RJ, Merkx MAW, et al. Integrated prediction and decision models are valuable in informing personalized decision making. J Clin Epidemiol. 2018;104:73\u201383. https:\/\/doi.org\/10.1016\/J.JCLINEPI.2018.08.016. PubMed PMID: 30170106.","journal-title":"J Clin Epidemiol"},{"issue":"10","key":"27723_CR13","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s40273-019-00817-1","volume":"37","author":"X Zang","year":"2019","unstructured":"Zang X, Krebs E, Wang L, Marshall BDL, Granich R, Schackman BR, et al. Structural design and data requirements for simulation modeling in HIV\/AIDS: a narrative review. PharmacoEconomics. 2019;37(10):1219. https:\/\/doi.org\/10.1007\/s40273-019-00817-1. PubMed PMID: 31222521.","journal-title":"PharmacoEconomics"},{"key":"27723_CR14","doi-asserted-by":"publisher","unstructured":"Zhukova A, Dunn D, Gascuel O. Modeling Drug Resistance Emergence and Transmission in HIV-1 in the UK. Viruses 2023, Vol 15,. 2023;15(6). https:\/\/doi.org\/10.3390\/v15061244. PubMed PMID: 37376544.","DOI":"10.3390\/v15061244"},{"key":"27723_CR15","doi-asserted-by":"publisher","unstructured":"Stannah J, Flores Anato JL, Pickles M, Larmarange J, Mitchell KM, Artenie A et al. From conceptualising to modelling structural determinants and interventions in HIV transmission dynamics models: a scoping review and methodological framework for evidence-based analyses. BMC Medicine 2024 22:1. 2024;22(1):404-. https:\/\/doi.org\/10.1186\/s12916-024-03580-z. PubMed PMID: 39300441.","DOI":"10.1186\/s12916-024-03580-z"},{"issue":"31, 2010","key":"27723_CR16","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1146\/ANNUREV.PUBLHEALTH.012809.103542\/CITE\/REFWORKS","volume":"31","author":"S Glied","year":"2010","unstructured":"Glied S, Tilipman N. Simulation modeling of health care policy. Annu Rev Public Health. 2010;31(31, 2010):439\u201355. https:\/\/doi.org\/10.1146\/ANNUREV.PUBLHEALTH.012809.103542\/CITE\/REFWORKS. PubMed PMID: 20235853.","journal-title":"Annu Rev Public Health"},{"key":"27723_CR17","doi-asserted-by":"publisher","unstructured":"Pirab\u00e1n-Ram\u00edrez A, Guerrero WJ, Labadie N, Sotaquir\u00e1-Guti\u00e9rrez R. A systemic model to assess shortage and wastage levels in demand-driven blood supply chains. Int J Healthc Manag. 2025;1\u201311. https:\/\/doi.org\/10.1080\/20479700.2024.2419280.","DOI":"10.1080\/20479700.2024.2419280"},{"issue":"1","key":"27723_CR18","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1057\/S41273-017-0062-0","volume":"12","author":"KM Long","year":"2018","unstructured":"Long KM, Meadows GN. Simulation modelling in mental health: A systematic review. J Simul. 2018;12(1):76\u201385. https:\/\/doi.org\/10.1057\/S41273-017-0062-0.","journal-title":"J Simul"},{"key":"27723_CR19","doi-asserted-by":"publisher","unstructured":"Glass T, Myer L, Lesosky M. The role of HIV viral load in mathematical models of HIV transmission and treatment: a review. BMJ Glob Health. 2020;5(1). https:\/\/doi.org\/10.1136\/BMJGH-2019-001800. PubMed PMID:.","DOI":"10.1136\/BMJGH-2019-001800"},{"key":"27723_CR20","doi-asserted-by":"publisher","unstructured":"Avance\u00f1a ALV, Hutton DW. Optimization Models for HIV\/AIDS Resource Allocation: A Systematic Review. Value Health. 2020;23(11):1509\u201321. https:\/\/doi.org\/10.1016\/J.JVAL.2020.08.001. PubMed PMID: 33127022.","DOI":"10.1016\/J.JVAL.2020.08.001"},{"issue":"1","key":"27723_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12976-019-0118-0\/FIGURES\/2","volume":"17","author":"X Sun","year":"2020","unstructured":"Sun X, Nishiura H, Xiao Y. Modeling methods for estimating HIV incidence: A mathematical review. Theor Biol Med Model. 2020;17(1):1\u201314. https:\/\/doi.org\/10.1186\/S12976-019-0118-0\/FIGURES\/2. PubMed PMID: 31964392.","journal-title":"Theor Biol Med Model"},{"key":"27723_CR22","doi-asserted-by":"publisher","unstructured":"Davahli MR, Karwowski W, Taiar R. A System Dynamics Simulation Applied to Healthcare: A Systematic Review. International Journal of Environmental Research and Public Health 2020, Vol 17, Page 5741. 2020;17(16):5741. https:\/\/doi.org\/10.3390\/IJERPH17165741. PubMed PMID: 32784439.","DOI":"10.3390\/IJERPH17165741"},{"issue":"1","key":"27723_CR23","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/S12992-022-00803-X","volume":"18","author":"WM Sweileh","year":"2022","unstructured":"Sweileh WM. Global research activity on mathematical modeling of transmission and control of 23 selected infectious disease outbreak. Global Health. 2022;18(1):4. https:\/\/doi.org\/10.1186\/S12992-022-00803-X. PubMed PMID: 35062966.","journal-title":"Global Health"},{"issue":"Suppl 1","key":"27723_CR24","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.4081\/idr.2013.s1.e5","volume":"5","author":"PS Pennings","year":"2013","unstructured":"Pennings PS. HIV Drug Resistance: Problems and Perspectives. Infect Dis Rep. 2013;5(Suppl 1):e5. https:\/\/doi.org\/10.4081\/idr.2013.s1.e5. PubMed PMID: 24470969.","journal-title":"Infect Dis Rep"},{"key":"27723_CR25","unstructured":"World Health Organization. News release. 2015. Treat all people living with HIV, offer antiretrovirals as additional prevention choice for people at substantial risk. Available from: https:\/\/www.who.int\/news\/item\/30-09-2015-treat-all-people-living-with-hiv-offer-antiretrovirals-as-additional-prevention-choice-for-people-at-substantial-risk?utm_source=chatgpt.com. Cited 12 May\u00a0 2025."},{"issue":"2","key":"27723_CR26","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1093\/infdis\/jit150","volume":"208","author":"UL Abbas","year":"2013","unstructured":"Abbas UL, Glaubius R, Mubayi A, Hood G, Mellors JW. Antiretroviral therapy and pre-exposure prophylaxis: Combined impact on HIV transmission and drug resistance in South Africa. J Infect Dis. 2013;208(2):224\u201334. https:\/\/doi.org\/10.1093\/infdis\/jit150. PubMed PMID: 23570850.","journal-title":"J Infect Dis"},{"key":"27723_CR27","doi-asserted-by":"publisher","unstructured":"Phillips AN, Cambiano V, Nakagawa F, Revill P, Jordan MR, Hallett TB et al. Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study. Lancet HIV. 2018;5(3):e146\u201354. https:\/\/doi.org\/10.1016\/S2352-3018(17)30190-X. PubMed PMID: 29174084.","DOI":"10.1016\/S2352-3018(17)30190-X"},{"key":"27723_CR28","doi-asserted-by":"publisher","unstructured":"Abbas UL, Glaubius RL, Ding Y, Hood G. Drug resistance from preferred antiretroviral regimens for HIV infection in South Africa: A modeling study. PLoS ONE. 2019;14(7). https:\/\/doi.org\/10.1371\/journal.pone.0218649. PubMed PMID: 31269034.","DOI":"10.1371\/journal.pone.0218649"},{"key":"27723_CR29","doi-asserted-by":"publisher","unstructured":"Cambiano V, Bertagnolio S, Jordan MR, Pillay D, Perri\u00ebns JH, Venter F et al. Predicted levels of HIV drug resistance: potential impact of expanding diagnosis, retention, and eligibility criteria for antiretroviral therapy initiation. AIDS. 2014;28 Suppl 1(SUPPL. 1). https:\/\/doi.org\/10.1097\/QAD.0000000000000082. PubMed PMID: 24468943.","DOI":"10.1097\/QAD.0000000000000082"},{"issue":"1","key":"27723_CR30","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/01.aids.0000433239.01611.52","volume":"28","author":"BE Nichols","year":"2014","unstructured":"Nichols BE, Sigaloff KCE, Kityo C, Mandaliya K, Hamers RL, Bertagnolio S, et al. Averted HIV infections due to expanded antiretroviral treatment eligibility offsets risk of transmitted drug resistance: A modeling study. AIDS. 2014;28(1):73\u201383. https:\/\/doi.org\/10.1097\/01.aids.0000433239.01611.52. PubMed PMID: 23921620.","journal-title":"AIDS"},{"key":"27723_CR31","doi-asserted-by":"publisher","unstructured":"Moeremans K, Hemmett L, Hjelmgren J, Allegri G, Smets E. Cost effectiveness of darunavir\/ritonavir 600\/100\u00a0mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK. Pharmacoeconomics. 2010;28 Suppl 1(SUPPL. 1):147\u201367. https:\/\/doi.org\/10.2165\/11587500-000000000-00000. PubMed PMID: 21182349.","DOI":"10.2165\/11587500-000000000-00000"},{"key":"27723_CR32","doi-asserted-by":"publisher","unstructured":"Brogan A, Mauskopf J, Talbird SE, Smets E. US cost effectiveness of darunavir\/ritonavir 600\/100\u00a0mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial. Pharmacoeconomics. 2010;28 Suppl 1(SUPPL. 1):129\u201346. https:\/\/doi.org\/10.2165\/11587490-000000000-00000. PubMed PMID: 21182348.","DOI":"10.2165\/11587490-000000000-00000"},{"key":"27723_CR33","doi-asserted-by":"publisher","unstructured":"Hauser A, Kusejko K, Johnson LF, Wandeler G, Riou J, Goldstein F, et al. Bridging the gap between hiv epidemiology and antiretroviral resistance evolution: Modelling the spread of resistance in south africa. PLoS Comput Biol. 2019;15(6). https:\/\/doi.org\/10.1371\/journal.pcbi.1007083. PubMed PMID: 31233494.","DOI":"10.1371\/journal.pcbi.1007083"},{"key":"27723_CR34","doi-asserted-by":"publisher","unstructured":"Kagay CR, Porco TC, Liechty CA, Charlebois E, Clark R, Guzman D, et al. Modeling the impact of modified directly observed antiretroviral therapy on HIV suppression and resistance, disease progression, and death. Clin Infect Dis. 2004;38Suppl 5(SUPPL. 5). https:\/\/doi.org\/10.1086\/421406. PubMed PMID: 15156432.","DOI":"10.1086\/421406"},{"key":"27723_CR35","doi-asserted-by":"publisher","unstructured":"Wilson DP, Kahn J, Blower SM. Predicting the epidemiological impact of antiretroviral allocation strategies in KwaZulu-Natal: The effect of the urban-rural divide. Proc Natl Acad Sci U S A. 2006;103(38):14228\u201333. https:\/\/doi.org\/10.1073\/PNAS.0509689103\/SUPPL_FILE\/09689FIG5.PDF. PubMed PMID: 16968786.","DOI":"10.1073\/PNAS.0509689103\/SUPPL_FILE\/09689FIG5.PDF"},{"key":"27723_CR36","doi-asserted-by":"publisher","unstructured":"Phillips A, Cambiano V, Nakagawa F, Magubu T, Miners A, Ford D, et al. Cost-effectiveness of HIV drug resistance testing to inform switching to second line antiretroviral therapy in low income settings. PLoS ONE. 2014;9(10). https:\/\/doi.org\/10.1371\/journal.pone.0109148. PubMed PMID: 25290340.","DOI":"10.1371\/journal.pone.0109148"},{"key":"27723_CR37","doi-asserted-by":"publisher","unstructured":"Duarte HA, Babigumira JB, Enns EA, Stauffer DC, Shafer RW, Beck IA et al. Cost-effectiveness analysis of pre-ART HIV drug resistance testing in Kenyan women. EClinicalMedicine. 2020;22. https:\/\/doi.org\/10.1016\/j.eclinm.2020.100355","DOI":"10.1016\/j.eclinm.2020.100355"},{"key":"27723_CR38","doi-asserted-by":"publisher","unstructured":"Hoare A, Kerr SJ, Ruxrungtham K, Ananworanich J, Law MG, Cooper DA, et al. Hidden drug resistant HIV to emerge in the era of universal treatment access in Southeast Asia. PLoS ONE. 2010;5(6). https:\/\/doi.org\/10.1371\/journal.pone.0010981. PubMed PMID: 20544022.","DOI":"10.1371\/journal.pone.0010981"},{"issue":"4","key":"27723_CR39","doi-asserted-by":"publisher","first-page":"e698","DOI":"10.1016\/S2214-109X(24)00553-9","volume":"13","author":"T Loosli","year":"2025","unstructured":"Loosli T, Han N, Hauser A, Josi J, Ingle SM, van Sighem A, et al. Predicted dolutegravir resistance in people living with HIV in South Africa during 2020\u201335: a modelling study. Lancet Glob Health. 2025;13(4):e698\u2013706. https:\/\/doi.org\/10.1016\/S2214-109X(24)00553-9. PubMed PMID: 40155107.","journal-title":"Lancet Glob Health"},{"issue":"2","key":"27723_CR40","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.1016\/S2352-3018(14)70021-9","volume":"1","author":"AN Phillips","year":"2014","unstructured":"Phillips AN, Cambiano V, Miners A, Revill P, Pillay D, Lundgren JD, et al. Effectiveness and cost-effectiveness of potential responses to future high levels of transmitted HIV drug resistance in antiretroviral drug-naive populations beginning treatment: Modelling study and economic analysis. Lancet HIV. 2014;1(2):e85\u201393. https:\/\/doi.org\/10.1016\/S2352-3018(14)70021-9.","journal-title":"Lancet HIV"},{"key":"27723_CR41","doi-asserted-by":"publisher","unstructured":"Rosen S, Long L, Sanne I, Stevens WS, Fox MP. The net cost of incorporating resistance testing into HIV\/AIDS treatment in South Africa: A Markov model with primary data. J Int AIDS Soc. 2011;14(1). https:\/\/doi.org\/10.1186\/1758-2652-14-24. PubMed PMID: 21575155.","DOI":"10.1186\/1758-2652-14-24"},{"issue":"12","key":"27723_CR42","doi-asserted-by":"publisher","first-page":"e2133","DOI":"10.1016\/S2214-109X(25)00350-X","volume":"13","author":"N Han","year":"2025","unstructured":"Han N, Loosli T, Anderegg N, Hauser A, Josi J, Davies MA, et al. The effect of long-acting cabotegravir and rilpivirine treatment on drug resistance in South Africa: a modelling study. Lancet Glob Health. 2025;13(12):e2133\u201343. https:\/\/doi.org\/10.1016\/S2214-109X(25)00350-X. PubMed PMID: 41240951.","journal-title":"Lancet Glob Health"},{"key":"27723_CR43","doi-asserted-by":"crossref","unstructured":"Bendavid E, Young SD, Katzenstein DA, Bayoumi AM, Sanders GD, Owens DK. Cost-Effectiveness of HIV Monitoring Strategies in Resource-Limited Settings. Arch Intern Med. 2008;168. Available from: http:\/\/healthpolicy.fsi.stanford.edu\/publications\/costeffectiveness_of_hiv_monitoring_strategies_in_resourcelimited_settings. Cited 5 Feb 2025.","DOI":"10.1001\/archinternmed.2008.1"},{"key":"27723_CR44","doi-asserted-by":"publisher","unstructured":"Glaubius RL, Parikh UM, Hood G, Penrose KJ, Bendavid E, Mellors JW, et al. Deciphering the Effects of Injectable Pre-exposure Prophylaxis for Combination Human Immunodeficiency Virus Prevention. Open Forum Infect Dis. 2016;3(3). https:\/\/doi.org\/10.1093\/OFID\/OFW125. PubMed PMID: 27703992.","DOI":"10.1093\/OFID\/OFW125"},{"key":"27723_CR45","doi-asserted-by":"publisher","unstructured":"Mauskopf J, Brogan A, Martin S, Smets E. Cost effectiveness of darunavir\/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA. Pharmacoeconomics. 2010;28(SUPPL. 1):83\u2013105. https:\/\/doi.org\/10.2165\/11587470-000000000-00000\/FIGURES\/TAB14. PubMed PMID: 21182346.","DOI":"10.2165\/11587470-000000000-00000\/FIGURES\/TAB14"},{"key":"27723_CR46","doi-asserted-by":"publisher","unstructured":"Lilian RR, Rees K, McIntyre JA, Struthers HE, Peters RPH. Same-day antiretroviral therapy initiation for HIV-infected adults in South Africa: Analysis of routine data. PLoS ONE. 2020;15(1). https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0227572. PubMed PMID: 31935240.","DOI":"10.1371\/JOURNAL.PONE.0227572"},{"key":"27723_CR47","doi-asserted-by":"publisher","unstructured":"Facha W, Tadesse T, Wolka E, Astatkie A. Viral load non-suppression status among women exposed to Dolutegravir-based versus Efavirenz-based regimens in Ethiopia: A before-and-after study. PLoS ONE. 2024;19(6). https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0305331. PubMed PMID: 38857273.","DOI":"10.1371\/JOURNAL.PONE.0305331"},{"issue":"1","key":"27723_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12889-024-20761-W","volume":"24","author":"A Gedefaw","year":"2024","unstructured":"Gedefaw A, Tadesse BT, Tadesse S, Kebede B, Hussen S, Hailu D, et al. The progress of mother-to-child transmission of Human Immunodeficiency Virus (HIV) after Dolutegravir (DTG) optimization program: evidence from a multicenter cohort study in Ethiopia. BMC Public Health 2024. 2024;24(1):1. https:\/\/doi.org\/10.1186\/S12889-024-20761-W.","journal-title":"BMC Public Health 2024"},{"key":"27723_CR49","doi-asserted-by":"publisher","unstructured":"Ismael N, Gemusse H, Mahumane I, Laurindo O, Magul C, Baxter C, et al. HIV-1 pretreatment and acquired antiretroviral drug resistance before tenofovir\/ \/lamivudine \/dolutegravir (TLD) roll-out in Mozambique. BMC Infect Dis. 2024;24(1). https:\/\/doi.org\/10.1186\/S12879-024-09579-4. PubMed PMID: 39075381.","DOI":"10.1186\/S12879-024-09579-4"},{"issue":"6","key":"27723_CR50","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1093\/INFDIS\/JIW219","volume":"214","author":"TS Boender","year":"2016","unstructured":"Boender TS, Hamers RL, Ondoa P, Wellington M, Chimbetete C, Siwale M, et al. Protease Inhibitor Resistance in the First 3 Years of Second-Line Antiretroviral Therapy for HIV-1 in Sub-Saharan Africa. J Infect Dis. 2016;214(6):873\u201383. https:\/\/doi.org\/10.1093\/INFDIS\/JIW219. PubMed PMID: 27402780.","journal-title":"J Infect Dis"},{"issue":"1","key":"27723_CR51","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/S41669-019-0157-9","volume":"4","author":"S Boyer","year":"2020","unstructured":"Boyer S, Nishimwe ML, Sagaon-Teyssier L, March L, Koulla-Shiro S, Bousmah MQ, et al. Cost-Effectiveness of Three Alternative Boosted Protease Inhibitor-Based Second-Line Regimens in HIV-Infected Patients in West and Central Africa. Pharmacoecon Open. 2020;4(1):45\u201360. https:\/\/doi.org\/10.1007\/S41669-019-0157-9. PubMed PMID: 31273686.","journal-title":"Pharmacoecon Open"},{"issue":"9","key":"27723_CR52","doi-asserted-by":"publisher","first-page":"e384","DOI":"10.1016\/S2352-3018(17)30069-3","volume":"4","author":"L Ciaffi","year":"2017","unstructured":"Ciaffi L, Koulla-Shiro S, Sawadogo AB, Ndour CT, Eymard-Duvernay S, Mbouyap PR, et al. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286\/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial. Lancet HIV. 2017;4(9):e384\u201392. https:\/\/doi.org\/10.1016\/S2352-3018(17)30069-3. PubMed PMID: 28566227.","journal-title":"Lancet HIV"},{"issue":"4","key":"27723_CR53","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1097\/COH.0000000000000746","volume":"17","author":"UM Parikh","year":"2022","unstructured":"Parikh UM, Mellors JW. How could HIV-1 drug resistance impact preexposure prophylaxis for HIV prevention? Curr Opin HIV AIDS. 2022;17(4):213\u201321. https:\/\/doi.org\/10.1097\/COH.0000000000000746. PubMed PMID: 35762376.","journal-title":"Curr Opin HIV AIDS"},{"key":"27723_CR54","doi-asserted-by":"publisher","unstructured":"Parikh UM, Koss CA, Mellors JW. Long-Acting Injectable Cabotegravir for HIV Prevention: What Do We Know and Need to Know about the Risks and Consequences of Cabotegravir Resistance?. Curr HIV\/AIDS Rep. 2022;19(5):384\u201393. https:\/\/doi.org\/10.1007\/S11904-022-00616-Y\/TABLES\/2. PubMed PMID: 36112336.","DOI":"10.1007\/S11904-022-00616-Y\/TABLES\/2"},{"key":"27723_CR55","doi-asserted-by":"publisher","unstructured":"Bulterys MA, Oyaro P, Brown E, Yongo N, Karauki E, Wagude J, et al. Costs of Point-of-Care Viral Load Testing for Adults and Children Living with HIV in Kenya. Diagnostics (Basel). 2021;11(1). https:\/\/doi.org\/10.3390\/DIAGNOSTICS11010140. PubMed PMID: 33477850.","DOI":"10.3390\/DIAGNOSTICS11010140"},{"key":"27723_CR56","doi-asserted-by":"publisher","unstructured":"Laxmeshwar C, Acharya S, Das M, Keskar P, Pazare A, Ingole N, et al. Routine viral load monitoring and enhanced adherence counselling at a public ART centre in Mumbai, India. PLoS ONE. 2020;15(5). https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0232576. PubMed PMID: 32369504.","DOI":"10.1371\/JOURNAL.PONE.0232576"},{"issue":"2 February","key":"27723_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0264463","volume":"17","author":"A Kiekens","year":"2022","unstructured":"Kiekens A, de Casterl\u00e9 BD, Vandamme AM. Qualitative systems mapping for complex public health problems: A practical guide. PLoS ONE. 2022;17(2 February):1\u20139. https:\/\/doi.org\/10.1371\/journal.pone.0264463. PubMed PMID: 35213648.","journal-title":"PLoS ONE"},{"issue":"12","key":"27723_CR58","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.3390\/PATHOGENS10121535","volume":"10","author":"A Kiekens","year":"2021","unstructured":"Kiekens A, Mosha IH, Zlati\u0107 L, Bwire GM, Mangara A, Dierckx de Casterl\u00e9 B, et al. Factors Associated with HIV Drug Resistance in Dar es Salaam, Tanzania: Analysis of a Complex Adaptive System. Pathogens 2021. Page 1535. 2021;10(12):1535. https:\/\/doi.org\/10.3390\/PATHOGENS10121535.","journal-title":"Page 1535"},{"issue":"2","key":"27723_CR59","doi-asserted-by":"publisher","first-page":"e116","DOI":"10.1016\/S2352-3018(18)30317-5","volume":"6","author":"AN Phillips","year":"2019","unstructured":"Phillips AN, Venter F, Havlir D, Pozniak A, Kuritzkes D, Wensing A, et al. Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study. Lancet HIV. 2019;6(2):e116\u201327. https:\/\/doi.org\/10.1016\/S2352-3018(18)30317-5. PubMed PMID: 30503325.","journal-title":"Lancet HIV"},{"key":"27723_CR60","unstructured":"World Health Organization. HIV, Drug Resistance S. 2021 Update. 2020. Available from: https:\/\/www.who.int\/publications\/b\/56037. Cited 21 Jan 2025."},{"issue":"1","key":"27723_CR61","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/COH.0000000000000209","volume":"11","author":"UM Parikh","year":"2016","unstructured":"Parikh UM, Mellors JW. Should we fear resistance from tenofovir\/emtricitabine preexposure prophylaxis? Curr Opin HIV AIDS. 2016;11(1):49\u201355. https:\/\/doi.org\/10.1097\/COH.0000000000000209. PubMed PMID: 26633640.","journal-title":"Curr Opin HIV AIDS"},{"issue":"18","key":"27723_CR62","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1097\/01.AIDS.0000433237.63560.20","volume":"27","author":"DAMCV Vijver","year":"2013","unstructured":"Vijver DAMCV, De, Nichols BE, Abbas UL, Boucher CAB, Cambiano V, Eaton JW, et al. Preexposure prophylaxis will have a limited impact on HIV-1 drug resistance in sub-Saharan Africa: a comparison of mathematical models. AIDS. 2013;27(18):2943\u201351. https:\/\/doi.org\/10.1097\/01.AIDS.0000433237.63560.20. PubMed PMID: 23939237.","journal-title":"AIDS"},{"key":"27723_CR63","doi-asserted-by":"publisher","unstructured":"Gibas KM, van den Berg P, Powell VE, Krakower DS. Drug Resistance During HIV Pre-Exposure Prophylaxis. Drugs. 2019;79(6):609\u201319. https:\/\/doi.org\/10.1007\/S40265-019-01108-X. PubMed PMID: 30963509.","DOI":"10.1007\/S40265-019-01108-X"},{"issue":"7","key":"27723_CR64","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41431-018-0160-0b","volume":"26","author":"M Boeckhout","year":"2018","unstructured":"Boeckhout M, Zielhuis GA, Bredenoord AL. The FAIR guiding principles for data stewardship: fair enough? Eur J Hum Genet 2018. 2018;26(7):7. https:\/\/doi.org\/10.1038\/s41431-018-0160-0b. PubMed PMID: 29777206.","journal-title":"Eur J Hum Genet 2018"},{"key":"27723_CR65","doi-asserted-by":"publisher","DOI":"10.1093\/EURPUB\/CKAA166.504","author":"L V\u00e1 Zquez Navarrete","year":"2020","unstructured":"V\u00e1 Zquez Navarrete L, Vargas I, Eguiguren P, Mogoll\u00f3 N-P\u00e9 Rez A, Samico I, Bertolotto F, et al. Challenges to effective governance in developing health systems: a qualitative study in Malawi. Eur J Public Health. 2020;30(Supplement_5). https:\/\/doi.org\/10.1093\/EURPUB\/CKAA166.504.","journal-title":"Eur J Public Health"},{"issue":"1","key":"27723_CR66","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s44263-025-00143-z","volume":"3","author":"KR Moran","year":"2025","unstructured":"Moran KR, Lopez T, Del Valle SY. The future of pandemic modeling in support of decision making: lessons learned from COVID-19. BMC Global Public Health. 2025;3(1):24. https:\/\/doi.org\/10.1186\/s44263-025-00143-z.","journal-title":"BMC Global Public Health"},{"issue":"2","key":"27723_CR67","doi-asserted-by":"publisher","first-page":"112330","DOI":"10.1016\/j.rser.2022.112330","volume":"161","author":"L Hofbauer","year":"2022","unstructured":"Hofbauer L, McDowall W, Pye S. Challenges and opportunities for energy system modelling to foster multi-level governance of energy transitions. Renew Sustain Energy Rev. 2022;161(2):112330. https:\/\/doi.org\/10.1016\/j.rser.2022.112330.","journal-title":"Renew Sustain Energy Rev"},{"issue":"3","key":"27723_CR68","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/j.1468-0491.2008.00402.x","volume":"21","author":"A Duit","year":"2008","unstructured":"Duit A, Galaz V. Governance and complexity - Emerging issues for governance theory. Governance. 2008;21(3):311\u201335. https:\/\/doi.org\/10.1111\/j.1468-0491.2008.00402.x.","journal-title":"Governance"},{"issue":"1","key":"27723_CR69","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1186\/s12879-017-2521-7","volume":"17","author":"P Kennedy","year":"2017","unstructured":"Kennedy P, Aden T, Cheng PY, Moen A. Measuring influenza laboratory capacity: use of a tool to measure improvements. BMC Infect Dis. 2017;17(1):431. https:\/\/doi.org\/10.1186\/s12879-017-2521-7. PubMed PMID: 28619009.","journal-title":"BMC Infect Dis"},{"key":"27723_CR70","doi-asserted-by":"crossref","unstructured":"Trikalinos TA, Siebert U, Lau J. Decision-Analytic Modeling to Evaluate Benefits and Harms of Medical Tests\u2014Uses and Limitations. Medical Tests-White Paper Series. 2009. PubMed PMID: 21290781.","DOI":"10.1177\/0272989X09345022"},{"issue":"2","key":"27723_CR71","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1093\/ajcp\/aqw083","volume":"146","author":"HL Zhang","year":"2016","unstructured":"Zhang HL, Omondi MW, Musyoka AM, Afwamba IA, Swai RP, Karia FP, et al. Challenges of Maintaining Good Clinical Laboratory Practices in Low-Resource Settings: A Health Program Evaluation Framework Case Study From East Africa. Am J Clin Pathol. 2016;146(2):199\u2013206. https:\/\/doi.org\/10.1093\/ajcp\/aqw083. PubMed PMID: 27473737.","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"27723_CR72","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1080\/09537320500088666","volume":"17","author":"M Hobday","year":"2005","unstructured":"Hobday M. Firm-level innovation models: Perspectives on research in developed and developing countries. Technol Anal Strateg Manag. 2005;17(2):121\u201346. https:\/\/doi.org\/10.1080\/09537320500088666.","journal-title":"Technol Anal Strateg Manag"},{"issue":"3","key":"27723_CR73","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1136\/bmjgh-2019-002212","volume":"5","author":"D Maher","year":"2020","unstructured":"Maher D, Aseffa A, Kay S, Tufet Bayona M. External funding to strengthen capacity for research in low-income and middle-income countries: exigence, excellence and equity. BMJ Glob Health. 2020;5(3):2212. https:\/\/doi.org\/10.1136\/bmjgh-2019-002212. PubMed PMID:.","journal-title":"BMJ Glob Health"},{"key":"27723_CR74","doi-asserted-by":"publisher","unstructured":"Hoomans T, Fenwick EAL, Palmer S, Claxton K. Value of information and value of implementation: Application of an analytic framework to inform resource allocation decisions in metastatic hormone-refractory prostate cancer. Value in Health. 2009;12(2):315\u201324. https:\/\/doi.org\/10.1111\/j.1524-4733.2008.00431.x. PubMed PMID: 18657098.","DOI":"10.1111\/j.1524-4733.2008.00431.x"},{"issue":"6","key":"27723_CR75","doi-asserted-by":"publisher","first-page":"377","DOI":"10.3111\/13696998.2014.907170","volume":"17","author":"HW Tuffaha","year":"2014","unstructured":"Tuffaha HW, Gordon LG, Scuffham PA. Value of information analysis in healthcare: a review of principles and applications. J Med Econ. 2014;17(6):377\u201383. https:\/\/doi.org\/10.3111\/13696998.2014.907170. PubMed PMID: 24650041.","journal-title":"J Med Econ"},{"issue":"5","key":"27723_CR76","doi-asserted-by":"publisher","first-page":"e284","DOI":"10.1016\/S2352-3018(20)30315-5","volume":"8","author":"K Gigu\u00e8re","year":"2021","unstructured":"Gigu\u00e8re K, Eaton JW, Marsh K, Johnson LF, Johnson CC, Ehui E, et al. Trends in knowledge of HIV status and efficiency of HIV testing services in sub-Saharan Africa, 2000\u201320: a modelling study using survey and HIV testing programme data. Lancet HIV. 2021;8(5):e284\u201393. https:\/\/doi.org\/10.1016\/S2352-3018(20)30315-5. PubMed PMID: 33667411.","journal-title":"Lancet HIV"},{"issue":"6","key":"27723_CR77","doi-asserted-by":"publisher","first-page":"e0275560","DOI":"10.1371\/JOURNAL.PONE.0275560","volume":"18","author":"W Hladik","year":"2023","unstructured":"Hladik W, Stupp P, McCracken SD, Justman J, Ndongmo C, Shang J, et al. The epidemiology of HIV population viral load in twelve sub-Saharan African countries. PLoS ONE. 2023;18(6):e0275560. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0275560. PubMed PMID: 37363921.","journal-title":"PLoS ONE"},{"key":"27723_CR78","unstructured":"Joint United Nations Programme on HIV\/AIDS (UNAIDS). UNAIDS. 2014. Fast-Track - Ending the AIDS epidemic by 2030. Available from: https:\/\/www.unaids.org\/en\/resources\/documents\/2014\/JC2686_WAD2014report. Cited 2 Oct 2025."},{"issue":"1","key":"27723_CR79","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/SRES.2301","volume":"33","author":"E Rouwette","year":"2016","unstructured":"Rouwette E, Bleijenbergh I, Vennix J. Group Model-Building to Support Public Policy: Addressing a Conflicted Situation in a Problem Neighbourhood. Syst Res Behav Sci. 2016;33(1):64\u201378. https:\/\/doi.org\/10.1002\/SRES.2301.","journal-title":"Syst Res Behav Sci"},{"key":"27723_CR80","doi-asserted-by":"publisher","unstructured":"Ocloo J, Garfield S, Franklin BD, Dawson S. Exploring the theory, barriers and enablers for patient and public involvement across health, social care and patient safety: a systematic review of reviews. Health Res Policy Syst. 2021;19(1). https:\/\/doi.org\/10.1186\/S12961-020-00644-3. PubMed PMID: 33472647.","DOI":"10.1186\/S12961-020-00644-3"},{"key":"27723_CR81","unstructured":"Peters DH, Tran NT. Adam Taghreed. Implementation research in health: a practical guide. World Health Organization; 2013. p. 67."},{"issue":"Suppl 1","key":"27723_CR82","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/ODI.13584","volume":"26","author":"V Sharma Mahendra","year":"2020","unstructured":"Sharma Mahendra V, Ranauta A, Yuvraj A, Santella AJ, Taslim A, Doughty J. The role of patient and public involvement in oral health and HIV\/AIDS research, practice and policy. Oral Dis. 2020;26(Suppl 1):117\u201322. https:\/\/doi.org\/10.1111\/ODI.13584. PubMed PMID: 32862520.","journal-title":"Oral Dis"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-026-27723-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-026-27723-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-026-27723-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T22:52:10Z","timestamp":1783551130000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12889-026-27723-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":82,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["27723"],"URL":"https:\/\/doi.org\/10.1186\/s12889-026-27723-4","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"assertion":[{"value":"14 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2083"}}